Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 11;37(4):683–694. doi: 10.1007/s10557-021-07310-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Cost-effectiveness acceptability curves at different willingness-to-pay thresholds for cholesterol and triglyceride lowering treatment strategies in combination with statin. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and inflation adjusted to 2021 values. Willingness-to-pay threshold in €/QALY. Dotted lines present the willingness-to-pay threshold at which the probability of cost-effectiveness surpasses 95%. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALY quality-adjusted life year